ClinVar Miner

Submissions for variant NM_000517.6(HBA2):c.178G>C (p.Gly60Arg)

gnomAD frequency: 0.00003  dbSNP: rs41328049
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
3billion RCV002051788 SCV002318893 likely pathogenic alpha Thalassemia 2022-03-22 criteria provided, single submitter clinical testing Same or different nucleotide change resulting in same amino acid change has been previously reported to be associated with HBA2 related disorder (ClinVar ID: VCV000015688, PMID:15658192). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000439112, PMID:8237999). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.934>=0.6, 3CNET: 0.989>=0.75). A missense variant is a common mechanism . The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.0000305). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV003736541 SCV004563528 likely pathogenic not provided 2023-11-09 criteria provided, single submitter clinical testing The HBA2 c.178G>C; p.Gly60Arg variant (Hb Zurich Albisrieden, also known as Gly59Arg, when numbered from the mature protein, rs41328049, HbVar ID: 1199) is an unstable hemoglobin reported in the literatures in a heterozygous individual affected with hypochromic microcytosis with no symptoms (Dutly 2004, also see HbVar and references therein). Notably, homozygosity for this variant (Pedroso 2018) and compound heterozygosity with Southeast Asian deletion (Yang 2016) are associated with alpha thalassemia major or Hb H disease phenotypes. Additionally, the other variant at this codon (c.178G>A; p. Gly60Asp, also known as Hb Adana) has been reported in individuals with Hb H disease and are considered pathogenic (Guruk 1993). This variant is also reported in ClinVar (Variation ID: 15688) and is found in the general population with an overall allele frequency of 0.003% (4/131276 alleles, including 1 homozygote) in the Genome Aggregation Database. The amino acid substitution involves the glycine residue at a structurally critical position significantly affecting the stability of the hemoglobin (Dutly 2004, Scheps 2020, Sharma 2020). The glycine at codon 60 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.934). Based on available information, the p.Gly60Arg variant is considered to be likely pathogenic. References: Curuk MA et al. Hb Adana or alpha 2(59)(E8)Gly-->Asp beta 2, a severely unstable alpha 1-globin variant, observed in combination with the -(alpha)20.5 Kb alpha-thal-1 deletion in two Turkish patients. Am J Hematol. 1993 Dec;44(4):270-5. PMID: 8237999. Dutly F et al. A new highly unstable alpha chain variant causing alpha(+)-thalassemia: Hb Zurich Albisrieden [alpha59(E8)Gly-->Arg (alpha2)]. Hemoglobin. 2004;28(4):347-51. PMID: 15658192. Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Pedroso GA et al. Thalassemia major phenotype caused by HB Zürich-Albisrieden [a2 59(E8) Gly > Arg (HBA2:C.178G > C)] in a Brazilian child. Pediatr Blood Cancer. 2018 Dec;65(12):e27413. PMID: 30151892. Scheps KG et al. Curating the gnomAD database: Report of novel variants in the globin-coding genes and bioinformatics analysis. Hum Mutat. 2020 Jan;41(1):81-102. PMID: 31553106. Sharma P et al. HbH disease due to compound heterozygosity for hemoglobins Zürich-Albisrieden and Sallanches. Pediatr Blood Cancer. 2020 Apr;67(4):e28161. PMID: 31930682. Yang X et al. Hydrops Fetalis Associated with Compound Heterozygosity for Hb Zurich-Albisrieden (HBA2: C.178G?>?C) and the Southeast Asian (- -SEA/) Deletion. Hemoglobin. 2016 Sep;40(5):353-355. PMID: 27686733.
OMIM RCV000016978 SCV000037250 other HEMOGLOBIN ZURICH ALBISRIEDEN 2016-10-13 no assertion criteria provided literature only
OMIM RCV000016979 SCV000037251 pathogenic Alpha-thalassemia, Dutch type 2004-01-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.